All In Biotech

Drug Trial Radar · NCT03611556

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Jun 21, 2018

Primary completion

Jul 22, 2022

Study completion Jul 22, 2022

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 101 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Conditions

  • Carcinoma
  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • OleclumabDrug

    Participants will receive IV infusion of oleclumab as stated in arm description.

  • DurvalumabDrug

    Participants will receive IV infusion of durvalumab as stated in arm description.

  • GemcitabineDrug

    Participants will receive IV infusion of gemcitabine as stated in arm description.

  • Nab-paclitaxelDrug

    Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

  • OxaliplatinDrug

    Participants will receive IV infusion of oxaliplatin as stated in arm description.

  • Folinic acidDrug

    Participants will receive IV infusion of folinic acid as stated in arm description.

  • 5-FUDrug

    Participants will receive IV infusion of 5-FU as stated in arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
  2. Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation PhaseTime frame: From Day 1 to 28 days after the first dose of study drugs
  3. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
  4. Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
  5. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
  6. Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion PhaseTime frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Fort Myers, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Buffalo, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Blacktown, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Oslo, Norway

  • Research Site

    Barcelona, Spain

  • Research Site

    Fuenlabrada, Spain

  • Research Site

    Oviedo, Spain

  • Research Site

    Pamplona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.